Back to News
Market Impact: 0.25
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
Vanda Pharmaceuticals reported a quarterly loss of $0.37 per share, narrower than the Zacks consensus estimate of a $0.72 loss. The loss was nearly unchanged from $0.38 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VNDA0.40
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft's Big Bets on AI Start to Pay Off
- Asian shares fall as Alphabet earnings miss drags Wall St futures lower
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off